Book Google Scholar. Macarron, R. Impact of high-throughput screening in biomedical research. Beck, A. Strategies and challenges for the next generation of therapeutic antibodies. Algire, G. Vascular reactions of normal and malignant tissues in vivo. Vascular reactions of mice to wounds and to normal and neoplastic transplants. Natl Cancer Inst. Greenblatt, M. Tumor angiogenesis — transfilter diffusion studies in hamster by transparent chamber technique.
Folkman, J. Tumor angiogenesis — therapeutic implications. Senger, D. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science , — Leung, D. Vascular endothelial growth factor is a secreted angiogenic mitogen. Presta, L.
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. Buchdunger, E. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Nowell, P. A minute chromosome in human chronic granulocytic leukemia. Science , Rowley, J. New consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining.
Nature , — Shtivelman, E. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Burnett, D. Hopkins, A. The druggable genome. Lokey, R. Forward chemical genetics: progress and obstacles on the path to a new pharmacopoeia.
Hall, S. Chemoproteomics-driven drug discovery: addressing high attrition rates. Today 11 , — Pruss, R. Phenotypic screening strategies for neurodegenerative diseases: a pathway to discover novel drug candidates and potential disease targets or mechanisms. CNS Neurol. Drug Targets 9 , — St Onge, R. Forward chemical genetics in yeast for discovery of chemical probes targeting metabolism. Molecules 17 , — Heitman, J. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast.
Sams-Dodd, F. Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. This paper discusses potential reasons for the high failure rate of target-based drug discovery and suggests changes to improve productivity.
Lee, J. Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches. Carragher, N. Combining imaging and pathway profiling: an alternative approach to cancer drug discovery. Today 17 , — Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. Chatterjee, A. Back to the future: lessons learned in modern target-based and whole-cell lead optimization of antimalarials.
Payne, D. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Fishman, M. Pharmaceuticals: a new grammar for drug discovery. Welch, E. PTC targets genetic disorders caused by nonsense mutations. Nature , 87—91 Rottmann, M. Spiroindolones, a potent compound class for the treatment of malaria. Butchbach, M. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy.
Chen, B. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nature Chem. Filippakopoulos, P. Selective inhibition of BET bromodomains. Gao, M. Nature , 96— This paper describes the discovery of daclatasvir BMS by phenotypic screening and further chemical optimization in the absence of target knowledge. Fusion Inhibitors. March 13, CCR5 Antagonists. August 6, January 22, August 13, October 12, Isentress HD.
May 26, Attachment Inhibitors. Post-Attachment Inhibitors. Post-attachment inhibitors block CD4 receptors on the surface of certain immune cells that HIV needs to enter the cells. March 6, Pharmacokinetic Enhancers. September 24, Combination HIV Medicines. August 2, August 22, November 14, The drug labeling on this Web site may not be the labeling on currently distributed products or identical to the labeling that is approved.
Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies described in monographs. Drugs marked "unapproved medical gas", "unapproved homeopathic" or "unapproved drug other" on this Web site have not been evaluated by FDA for safety and efficacy and their labeling has not been approved.
In addition, FDA is not aware of scientific evidence to support homeopathy as effective. The device labeling and other device-specific information on this website have been voluntarily submitted to the FDA by device manufacturers.
FDA has not reviewed this information prior to posting on this website.
0コメント